<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353625</url>
  </required_header>
  <id_info>
    <org_study_id>CC-115-ST-001</org_study_id>
    <nct_id>NCT01353625</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.</brief_title>
  <official_title>A Phase 1a/1b, Multicenter, Open Label, Dosefinding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual Dna-pk and Tor Kinase Inhibitor, Cc-115, Administered Orally to Subjects With Advanced Solid Tumors and Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this first human study with CC-115 is to assess the safety and action of
      a new class of experimental drug (dual DNA-PK and TOR kinase inhibitors) in patients with
      advanced tumors unresponsive to standard therapies and to determine the appropriate dose and
      tumor types for later-stage clinical trials. The bioavailability of tablet and capsule
      formulations under fasting and fed conditions will also be evaluated in some patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Latest amendment clarifies that Chronic Lymophocytic Leukemia (CLL) includes T-cell
      Prolymphocytic Leukemia (T-PLL). Prior treatment with some drugs targeting mTOR, P13K and
      related pathways is now permitted.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 25, 2011</start_date>
  <completion_date type="Anticipated">November 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Limiting Toxicity</measure>
    <time_frame>Continuously for 28 days after starting treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-Tolerated Dose</measure>
    <time_frame>Continuously for 28 days after starting treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Continuously for 28 days after starting treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration in Plasma of CC-115</measure>
    <time_frame>Days 1, 2, 15, 16 of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve for CC-115</measure>
    <time_frame>Days 1, 2, 15 and 16 of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Concentration of CC-115</measure>
    <time_frame>Days 1, 2, 15, and 16 of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-Life for CC-115</measure>
    <time_frame>Days 1, 2, 15, and 16 of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Body Clearance of CC-115</measure>
    <time_frame>Days 1, 2, 15 and 16 of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution of CC-115</measure>
    <time_frame>Days 1, 2, 15, and 16 of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Index of CC-115</measure>
    <time_frame>Days 1, 2, 15 and 16 of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Screening (within 28 days prior to first dose of study drug) and Days 1, 2, 8, 15, 22, 28, 155, and end of treatment</time_frame>
    <description>Phosphorylation inhibition determined by changes in the levels of multiple biomarkers including S6 and, 4EBP (for mTORC1), AKT (for mTORC2) and other appropriate biomarkers in circulating granulocytes and tumor tissue (when available).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Tumor Efficacy</measure>
    <time_frame>Every 2-3 months until proof of tumor progression</time_frame>
    <description>Tumor response rates using appropriate objective criteria for various malignancies</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <condition>Prostate Cancer</condition>
  <condition>Ewing's Osteosarcoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>CC-115</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-115</intervention_name>
    <description>Part A (actively recruiting): Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity).
Part B: Optimal dose schedule is administered in 28-day cycles until disease progression.</description>
    <arm_group_label>CC-115</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically-confirmed advanced solid tumor, chronic lymphocytic leukemia, small
             lymphocytic lymphoma, T-cell prolymphocytic leukemia, Non-Hodgkin Lymphoma or multiple
             myeloma

          -  Progressed or not tolerated standard therapy, and no further standard therapy is
             available

          -  Archival and screening tumor biopsy

          -  Eastern Cooperative Oncology Group Performance Status: 0 or 1

          -  Adequate organ function

        Exclusion Criteria:

          -  Prior cancer-directed modalities or investigational drugs within 4 wks or 5 half
             lives, whichever is shorter

          -  Symptomatic brain metastases (prior treatment and stable metastases are allowed)

          -  Acute or chronic renal disease or pancreatitis

          -  Diarrhea ≥ Grade 2, impaired gastrointestinal absorption

          -  Impaired cardiac function

          -  History of diabetes requiring treatment, glucose &gt;126 mg/dL, Glycated hemoglobin
             (HbA1c) ≥6.5%

          -  Peripheral neuropathy ≥ Grade 2

          -  Known Human Immunodeficiency Virus (HIV) infection, chronic hepatitis B or C (unless
             associated with hepatocellular cancer)

          -  Pregnant, inadequate contraception, breast feeding

          -  Most concurrent second malignancies

          -  Part B only: Prior treatment with agents targeting both mammalian target of rapamycin
             (mTOR) complexes (dual mammalian target of rapamycin complex 1/2 inhibitors) and/or
             PI3K/AKT pathways. However, prior treatment with isolated target of rapamycin complex
             1 (TORC1) inhibitors (eg., rapalogs) is allowed in both parts of this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristen Hege, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco Comprehensive Cancer Center and Cancer Research Institiute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute Drug Development Unit</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Koln</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Wurzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Donosti</name>
      <address>
        <city>San Sebastián (Guipuzcoa)</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2011</study_first_submitted>
  <study_first_submitted_qc>May 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2011</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasm</keyword>
  <keyword>Malignancy</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Multiple myeloma</keyword>
  <keyword>mTOR kinase inhibitor</keyword>
  <keyword>Castration-resistant prostate cancer</keyword>
  <keyword>Hormone-resistant prostate cancer</keyword>
  <keyword>Diffuse Large B-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

